| Specification- || Asparaginase is an enzyme that catalyzes the hydrolysis of asparagine to aspartic acid. It is used for the treatment of acute lymphoblastic leukemia (ALL) and is also used in some mast cell tumor protocols.  Unlike other chemotherapy agents, it can be given as an intramuscular, subcutaneous, or intravenous injection without fear of tissue irritation.|
| Indication : || Acute leukaemia, Malignant lymphoma.|
|Dosage :- || 50-200 k.u/kg body wt. daily or every alternate day by I.V infusion.|
|Contraindications:-|| Hypersensitivity or previous serious allergic reaction (such as generalized urticaria, bronchospasm, laryngeal edema, hypotension) to drug.|
Pancreatitis or history of pancreatitis.
Previous hemorrhagic events related to L-asparaginase therapy
|Precautions:- || renal or hepatic disease, CNS disorders.|
concurrent use of hepatotoxic agents, anticoagulants, aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs)
pregnant or breastfeeding patients.
| Drug interaction: || Vincristine and prednisolone increases the toxicity, diminishes or abolishes the effect of methotrexate on malignant cells.|
|Adverse Effect-: || The main side effect is an allergic or hypersensitivity reaction; anaphylaxis is a possibility. Asparaginase has also been associated with pancreatitis. Additionally, it can also be associated with a coagulopathy as it decreases protein synthesis, including synthesis of coagulation factors (eg progressive isolated decrease of fibrinogen) and anticoagulant factor (generally antithrombin III; sometimes protein C & S as well), leading to bleeding or thrombotic events such as stroke. |
|Storage:|| Store between +2°C and +8°C. |
| Purity:- || 100 % |